Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma

Leukemia

Volumn 26, Issue 5, 2012, Pages 1046-1052

  Ansell, S M ^a   Tang, H ^a   Kurtin, P J ^a   Koenig, P A ^b   Nowakowski, G S ^a   Nikcevich, D A ^b   Nelson, G D ^a   Yang, Z ^a   Grote, D M ^a   Ziesmer, S C ^a   Silberstein, P T ^b   Erlichman, C ^b   Witzig, T E ^a  

^a MAYO CLINIC   (United States)

^b North Central Cancer Treatment Group Rochester   (United States)

Author keywords

denileukin diftitox; Follicular lymphoma; rituximab

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CALCIUM; DENILEUKIN DIFTITOX; GLUCOSE; PHOSPHATE; RITUXIMAB; SODIUM;

ADULT; ADVANCED CANCER; ANGINA PECTORIS; ARTICLE; B LYMPHOCYTE; CANCER CELL; CANCER PATIENT; CAPILLARY LEAK SYNDROME; CATHETER INFECTION; CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; CONSCIOUSNESS LEVEL; DEHYDRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; ENTERITIS; FATIGUE; FEMALE; FOLLICULAR LYMPHOMA; HEART MUSCLE ISCHEMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERSENSITIVITY; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; LYMPHOCYTOPENIA; MALE; MUSCLE WEAKNESS; MYOSITIS; NEUTROPENIA; OUTCOME ASSESSMENT; PAIN; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTHROMBIN TIME; REGULATORY T LYMPHOCYTE; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; SYNCOPE; THORAX PAIN; THROMBOSIS; TREATMENT RESPONSE; VALVULAR HEART DISEASE; WOUND INFECTION;

EID: 84860713220     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.297     Document Type: Article

References (24)

1. Ansell SM, Stenson M, Habermann TM, Jelinek DF, Witzig TE. CD4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J Clin Oncol 2001; 19: 720-726.
2. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25T cells. Blood 2007; 110: 2537-2544.
3. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res 2009; 69: 5522-5530.
4. Yang ZZ, Novak AJ, Stenson MJ, Witzig TE, Ansell SM. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T-cells in B-cell non-Hodgkin lymphoma. Blood 2006; 107: 3639-3646.
5. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res 2006; 66: 10145-10152.
6. Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000; 48: 673-683.
7. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95: 3900-3908.
8. Wurflein D, Dechant M, Stockmeyer B, Tutt AL, Hu P, Repp R et al. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells. Cancer Res 1998; 58: 3051-3058.
9. Hainsworth JD, Litchy S, Burris III HA, Scullin Jr DC, Corso SW, Yardley DA et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol 2002; 20: 4261-4267.
10. Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma-a randomized phase II trial of the Minnie Pearl Cancer Res Network. J Clin Oncol 2005; 23: 1088-1095.
11. Martinelli G, Schmitz SF, Utiger U, Cerny T, Hess U, Bassi S et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010; 28: 4480-4484.
12. Witzig TE, Vukov AM, Habermann TM, Geyer S, Kurtin PJ, Friedenberg WR et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol. 2005; 23: 1103-1108.
13. Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D et al. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 4095-4102.
14. Dang NH, Fayad L, McLaughlin P, Romaguara JE, Hagemeister F, Goy A et al. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. Br J Haematol 2007; 138: 502-505.
15. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244-1253.
16. Sargent DJ, Chan V, Goldberg RM. A three-outcome design for phase II clinical trials. Control Clin Trials 2001; 22: 117-125.
17. Kaplan E, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
18. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258-1265.
19. Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002; 2: 389-400.
20. Morse MA, Clay TM, Mosca P, Lyerly HK. Immunoregulatory T cells in cancer immunotherapy. Expert Opin Biol Ther 2002; 2: 827-834.
21. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169: 2756-2761.
22. Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL et al. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002; 168: 4272-4276.
23. Vang KB, Yang J, Mahmud SA, Burchill MA, Vegoe AL, Farrar MA. IL-2,-7, and-15, but not thymic stromal lymphopoeitin, redundantly govern CD4+Foxp3+ regulatory T cell development. J Immunol 2008; 181: 3285-3290.
24. Sarween N, Chodos A, Raykundalia C, Khan M, Abbas AK, Walker LS. CD4+CD25+ cells controlling a pathogenic CD4 response inhibit cytokine differentiation, CXCR-3 expression, and tissue invasion. J Immunol 2004; 173: 2942-2951.